- Oxford Biomedica
- 23 June 2025 11:20:13
Source: Sharecast
The London-listed cell and gene therapy contract development and manufacturing organisation (CDMO) exercised its call option in March to acquire the final interest in the Bedford, Massachusetts-based entity.
It said the stake was originally held by Homology Medicines, which merged with Q32 Bio in 2024.
OXB US was established in 2022 as an adeno-associated virus (AAV) manufacturing and innovation site, and had since been fully integrated into Oxford Biomedica’s global network. The 96,000 square foot facility now offered both lentiviral and AAV vector capabilities and had successfully onboarded several new programmes in the US.
Oxford Biomedica said its lentiviral platform was transferred to the site in 2024.
“The progression to full ownership of our US business marks an important step for OXB,” said chief executive officer Dr Frank Mathias.
“It strengthens our position in a key market and helps meet growing demand for high-quality vector manufacturing - a critical enabler of the expanding cell and gene therapy market.”
Dr Mathias said the company’s presence in the US, alongside its existing sites in the UK and France, gave clients access to “deep expertise” across AAV and lentiviral-based therapies.
“Through OXB’s network, we are able to support clients globally across all key vector types - from early-stage development through to commercialisation.”
At 1102 BST, shares in Oxford Biomedica were down 2.96% at 311.5p.
Reporting by Josh White for Sharecast.com.